High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study.

Transl Oncol · 2025 · PMC12391425 · PMID 40829267

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

showed a trendP = 0.058so close (0.05 < p ≤ 0.1)

did not reach statistical significanceno p-value reported

In this study, patients who received radiotherapy during systemic treatment showed a trend toward improved iPFS compared with those who underwent radiotherapy prior to starting this regimen (P = 0.058), although this did not reach statistical significance due to the retrospective design and limited sample size( supplement Figure2 ).

also in 33,481 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.